The level of CD11c expression in CD8+ T cells can be a useful marker for evaluation of the degree of expansion and the quality of tumor-specific CTLs as well as a marker to predict the efficacy of anti-tumor immunotherapies. This evidence concerns the gene ITGAX and neoplasm.